Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Editas Medicine Inc | EDIT | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
5.51 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 4.91 - 11.91 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 5.51 | USD |
Editas Medicine (EDIT) Options Flow Summary
Editas Medicine Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
450.79M | 81.81M | - | 78.12M | -153.22M | -1.87 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Editas Medicine News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EDIT Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 6.09 | 6.69 | 5.38 | 5.75 | 1,707,893 | -0.58 | -9.52% |
1 Month | 5.51 | 6.69 | 4.91 | 5.50 | 1,862,257 | 0.00 | 0.00% |
3 Months | 10.24 | 11.58 | 4.91 | 7.19 | 2,016,137 | -4.73 | -46.19% |
6 Months | 10.29 | 11.69 | 4.91 | 8.24 | 1,884,390 | -4.78 | -46.45% |
1 Year | 9.23 | 11.91 | 4.91 | 8.38 | 1,832,526 | -3.72 | -40.30% |
3 Years | 33.55 | 73.025 | 4.91 | 17.64 | 1,775,808 | -28.04 | -83.58% |
5 Years | 22.75 | 99.95 | 4.91 | 25.00 | 1,544,472 | -17.24 | -75.78% |
Editas Medicine Description
Editas Medicine Inc is a gene-editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company's only operating segment is developing and commercializing genome editing technology. |